clinical trial · NCT07867080
A Phase 3 Trial for Intravitreal Injection of 4D-150 in Adults With Diabetic Macular Edema (DME).
Diabetic Macular Edema (DME)4D-150 IVT (3x10^10 vg)EYELEA ® (aflibercept) Injection 2 mg (0.05mL)
brief summary
A Phase 3, Randomized, Double-Masked, Active-Controlled Trial to Evaluate the Safety, Efficacy, and Durability of a Single Intravitreal Injection of 4D-150 versus Aflibercept in Adults with Diabetic Macular Edema (4SIGHT)
started
Sep 18, 2026
primary completion
Jan 1, 2029
completion
Jan 1, 2030
last updated
Nov 18, 2026
official title
A Phase 3, Randomized, Double-Masked, Active-Controlled Trial to Evaluate the Efficacy, Safety, and Durability of a Single Intravitreal Injection of 4D-150 Versus Aflibercept in Adults With Diabetic Macular Edema (4SIGHT)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol